Is NCT03310463 results overdue?

Yes — results are overdue. Primary completion was 2018-05-25; the FDAAA-801 reporting deadline (2019-05-25) passed 2630 days ago and no results are posted on ClinicalTrials.gov.

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT ID	NCT03310463 ↗
Sponsor	Entasis Therapeutics (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2018-05-25 (ACTUAL)
Reporting deadline	2019-05-25 (completion + 365d)
Days overdue	2630
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `df0cea808404e4c7…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03310463. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.